Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cardiovasc Pathol ; 70: 107625, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38417471

RESUMO

Erdheim-Chester disease (ECD) is a rare histiocytosis characterized by the foamy CD68+CD1a- histiocytes infiltrating multiple organs and tissues. ECD might be asymptomatic or present with variable manifestations. The diagnosis of ECD requires characteristic radiological findings and pathological features. Herein, we described a 52-year-old female patient who was admitted to our hospital for recurrent pericardial effusion for two months. She has a medical history of papillary thyroid carcinoma (PTC) and underwent a total thyroidectomy two years before admission. The radiological findings suggested a potential diagnosis of ECD. Cytological analysis of the effusion cytology specimen revealed CD68+CD1a- histiocytes, confirming the ECD diagnosis. The BRAF V600E mutation was identified in the histiocytes, prompting the administration of vemurafenib, a BRAF inhibitor. After two months of standard-dose vemurafenib treatment, the disease was well controlled with pericardial effusion regression.


Assuntos
Doença de Erdheim-Chester , Derrame Pericárdico , Proteínas Proto-Oncogênicas B-raf , Vemurafenib , Feminino , Humanos , Pessoa de Meia-Idade , Doença de Erdheim-Chester/genética , Doença de Erdheim-Chester/tratamento farmacológico , Doença de Erdheim-Chester/complicações , Doença de Erdheim-Chester/patologia , Doença de Erdheim-Chester/diagnóstico , Histiócitos/patologia , Mutação , Derrame Pericárdico/patologia , Derrame Pericárdico/etiologia , Valor Preditivo dos Testes , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Proto-Oncogênicas B-raf/genética , Resultado do Tratamento , Vemurafenib/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA